FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s
Eisai Co., Ltd. and Biogen Inc. announced that the FDA has approved the Biologics License Application (BLA) for LEQEMBI IQLIK (lecanemab-irmb), a once-weekly 360 mg subcutaneous autoinjector designed for maintenance dosing in patients with early Alzheimer’s disease. The device, which administers treatment in approximately 15 seconds, offers patients an alternative to intravenous (IV) infusions.
“We believe LEQEMBI IQLIK represents a major step forward in patient-centered Alzheimer’s care,” said Haruo Naito, CEO of Eisai. “By providing a simple at-home option, we are e...